Leadership

CV6 Therapeutics is led by a multidisciplinary team of scientists, clinicians, drug developers, and experienced industry leaders with a track record of advancing innovative therapies from discovery through clinical development.

block: text

Supported by a distinguished board and advisors across oncology, translational medicine, and strategic investment, the team brings deep expertise across biology, chemistry, and clinical execution, focused on delivering meaningful impact for patients and building long-term value.

block: team-listing

Richard Wilson, MD

Advisor 2

Paul Workman, PhD

Advisor 1

Robert D Ladner, PhD

Chief Executive Officer & Founder

Richard Milliken, CA

Chairman of the Board

Robert Comfort, JD

Chairman of the Board

Chris E. Rivera

Board Member

Chris Takimoto, MD, PhD

Independent Board Member

Mike Hennessy

Board Member

Karl Mulligan, PhD

Chief Operating Officer & Co-Founder

Ruth Plummer, MD

Advisor Role

Iain McInnes, CBE

Advisor Role

Ian Bruce, MD

Advisor Role

Michael Lewis, PhD

Advisor Role

Udai Banerji, MD, PhD

Advisor Role

Sebastian Stintzing, MD

Advisor Role

block: quotes

“”

Prof. Ruth Plummer, MD

If CV6-168 performs as expected, it could fundamentally change how we use 5-FU in cancer treatment.